Provided by Tiger Trade Technology Pte. Ltd.

BOAN BIOTECH

3.030
+0.1404.84%
Volume:424.60K
Turnover:1.25M
Market Cap:1.86B
PE:244.12
High:3.065
Open:2.890
Low:2.800
Close:2.890
52wk High:13.050
52wk Low:2.400
Shares:614.00M
HK Float Shares:614.00M
Volume Ratio:0.30
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.012
ROE:-4.11%
ROA:-1.28%
PB:0.60
PE(LYR):244.12
PS:2.54

Loading ...

BOAN BIOTECH Secures US Licensing Agreement for Dulaglutide Injection

Stock News
·
Jun 11

BRIEF-Shandong Boan Biotechnology Announces Licensing Of Dulaglutide Injection In US

Reuters
·
Jun 11

Shandong Boan Biotech licenses U.S. rights to dulaglutide biosimilar BA5101 to partner

Reuters
·
Jun 11

Shandong Boan Biotechnology Co Ltd - Licensing of Dulaglutide Injection in U.S.

THOMSON REUTERS
·
Jun 11

Boan Biotech: No Share Capital Changes in May; Public Float Remains Above 18.14% Waiver Threshold

Bulletin Express
·
Jun 03

BOAN BIOTECH Submits US Applications for Two Denosumab Biosimilars

Stock News
·
May 29

Shandong Boan Bio submits US FDA BLA for two denosumab biosimilars

Reuters
·
May 29

Shandong Boan Biotechnology Co Ltd - Bla Submission for Two Denosumab Biosimilars in U.S. to FDA

THOMSON REUTERS
·
May 29

Shandong Boan Biotechnology Co Ltd - Ba6101 Obtained Marketing Approved in Bolivia

THOMSON REUTERS
·
May 29

BOAN BIOTECH Sets 22 June 2026 AGM; Seeks Fresh Share Mandates and Launches 2% RSU Plan

Bulletin Express
·
May 27

BOAN BIOTECH Sets 22 June 2026 AGM; Seeks 20% Share Issuance Mandate, 10% Buy-Back Authority and RSU Scheme Approval

Bulletin Express
·
May 27

Shandong Boan Biotechnology announces annual shareholder meeting

Reuters
·
May 27

Shandong Boan Biotechnology Says Boluojia (Denosumab Injection) Approved By NMPA

Reuters
·
May 26

BOAN BIOTECH's Denosumab Injection BOLUOGA® Gains New Indication Approval in China

Stock News
·
May 26

Shandong Boan says China regulator approves expanded Boluojia use for bone metastases, multiple myeloma

Reuters
·
May 26

Shandong Boan Biotechnology Co Ltd - Boluojia (Denosumab Injection) Approved in China for Bone Metastases by Nmpa

THOMSON REUTERS
·
May 26

Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval

Stock Track
·
May 19

BOAN BIOTECH Shares Surge on Share Buyback Plan and New Drug Approval in Macau

Stock News
·
May 19

Boan Biotechnology Announces HK$200 Million Share Buyback

MT Newswires Live
·
May 14

Boan Biotech Announces Plan for On-Market Share Repurchase of up to HK$200 Million

Bulletin Express
·
May 13